

# Recombinant Human SLAMF7

Catalog No: #GP10323



Package Size: #GP10323-1 100ug

Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)

## Description

Product Name	Recombinant Human SLAMF7
Brief Description	Recombinant Protein
Immunogen Description	Fusion protein corresponding to a region derived from 23-226 amino acids of human SLAMF7
Target Name	SLAM family member 7
Other Names	19A; CS1; CD319; CRACC
Accession No.	Swissprot:Q9NQ25Gene Accession:BC027867
Uniprot	Q9NQ25
GeneID	57823;
Storage	-20~-80°C, pH 7.6 PBS

## Background

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform?1?mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).

## References

Note: For in vitro research use only, not for diagnostic or therapeutic use. This product is not a medical device.

Note: This product is for in vitro research use only